⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Urolithin A
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-11-10 — Urolithin A plus EGCG enhances mitophagy associated pathways, mitochondrial dynamics, and bioenergetic function in humanized amyloid-β knock-in mice.: [animal-model] A study in humanized amyloid-beta knock-in mice reported that urolithin A plus EGCG enhanced mitophagy-associated pathways, mitochondrial fusion, biogenesis and bioenergetic function, reduced amyloid-beta pathology and improved cognitive performance; it does not establish human cognitive or longevity benefits. [animal-model] (novelty: 3)
- 2026-10-05 — K21 Improves Mitochondrial Function in Macrophages, Extending Life in Nematode Worms: cross-connection with k21-antimicrobial: Shared mechanistic axis — enhancement of mitophagy as a putative healthspan lever, previously the signature claim for urolithin A and now proposed for K21. (novelty: 3)
- 2026-04-03 — A 3-N nose-to-brain urolithin a nanomotor targeting microglial mitophagy in neuroinflammation.: Preclinical nose-to-brain HMnO2/PDA biomimetic nanomotor delivering urolithin A enhanced microglial mitophagy and reduced neuroinflammation, oxidative stress, and cognitive deficits in LPS-induced cell and mouse models — a delivery/mechanism advance, no human data. [animal-model] (novelty: 3)
- 2026-07-17 — Is Urolithin A(UA) a pharmacologically credible neuro-nutraceutical? A critical review of mechanisms, brain exposure, and evidence gaps in Alzheimer’s and Parkinson’s disease.: Critical neuro-nutraceutical review concludes urolithin A has convergent preclinical support for PINK1/Parkin mitophagy restoration and reduced neuroinflammation in AD/PD models, and established human safety plus muscle/mitochondrial benefits, but zero completed cognitive or disease-modifying CNS trials — brain exposure and BBB penetration remain under-characterized. [mechanism-plausible] (novelty: 3)
- 2026-06-13 — Cyanidin chloride activates mitophagy to delay aging via PINK1/parkin pathway.: cross-connection with anthocyanins: Both are food-derived compounds now linked to PINK1/Parkin-mediated mitophagy activation as a putative geroprotective mechanism — cyanidin chloride joins urolithin A in the mitophagy-inducer group, though only urolithin A has human trial readouts. (novelty: 3)
- 2026-09-11 — Mitochondrial homeostasis in musculoskeletal diseases: From pathogenic mechanisms to precision therapies.: Musculoskeletal mitochondrial-homeostasis review casts urolithin A as the mitophagy-inducer arm of a precision therapy landscape for OP/OA/RA, targeting failed PINK1/Parkin clearance in chondrocytes, osteocytes, and myocytes — mechanistic synthesis, no new MSK outcome data. [mechanism-plausible] (novelty: 3)
- 2026-08-10 — Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers: 12-week RCT protocol registered testing daily urolithin A 500 mg alone or combined with fisetin (300+200 mg) vs placebo in middle-aged/older adults, with sleep quality and multi-modal aging biomarkers (methylation, inflammation, microbiome) as endpoints — design item, no readout. [expert-opinion] (novelty: 3)
- 2026-08-14 — Targeting TWEAK to enhance mitochondrial biogenesis and attenuate age-related muscle mass loss.: cross-connection with tweak-fn14: Both converge on skeletal muscle mitochondrial biogenesis as an anti-sarcopenia lever, though only urolithin A has human RCT readouts. (novelty: 3)
- 2026-07-03 — PROMETHEUS clinical trial protocol: tailoring healthy ageing with lifestyle and nutraceuticals.: PROMETHEUS feasibility trial (n=20, 8 weeks) assigns urolithin A as a gerotype-tailored augment for participants with baseline muscle deficits; no efficacy readout. [expert-opinion] (novelty: 3)
- 2026-07-29 — A Purified Lycii Fructus Polysaccharide Fraction Extends Healthspan inwith an ATFS-1/UBL-5-Associated Mitochondrial Unfolded Protein Response.: cross-connection with lycii-fructus-polysaccharide: Both converge on mitochondrial quality control as the proposed longevity mechanism — FSP via ATFS-1/UBL-5 mitochondrial UPR, urolithin A via mitophagy — making them useful comparators within the mitochondria-targeted intervention set. (novelty: 3)
- 2026-08-03 — Natural Bioactive Compounds Targeting Key Hallmarks of Aging: Functional Food Potential of Spermidine, Fisetin, Berberine, and Urolithin A.: Narrative review assigns urolithin A the mitophagy role in a proposed functional-food combination with spermidine, fisetin, and berberine targeting complementary hallmarks of aging; no co-administration studies cited. [mechanism-plausible] (novelty: 3)
Open questions
Related
Contributing findings
Urolithin A plus EGCG enhances mitophagy associated pathways, mitochondrial dynamics, and bioenergetic function in humanized amyloid-β knock-in mice.
10-nov-2026
novelty 3
per-area 3
strengthens
Mitochondrial homeostasis in musculoskeletal diseases: From pathogenic mechanisms to precision therapies.
11-sep-2026
novelty 3
per-area 3
strengthens
Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers
10-aug-2026
novelty 3
per-area 3
strengthens
Natural Bioactive Compounds Targeting Key Hallmarks of Aging: Functional Food Potential of Spermidine, Fisetin, Berberine, and Urolithin A.
03-aug-2026
novelty 3
per-area 3
strengthens
Senomorphic agents: Multi-target strategies to tame the senescence-associated secretory phenotype for healthy ageing.
24-jul-2026
novelty 2
per-area 2
strengthens
Is Urolithin A(UA) a pharmacologically credible neuro-nutraceutical? A critical review of mechanisms, brain exposure, and evidence gaps in Alzheimer's and Parkinson's disease.
17-jul-2026
novelty 3
per-area 3
strengthens
PROMETHEUS clinical trial protocol: tailoring healthy ageing with lifestyle and nutraceuticals.
03-jul-2026
novelty 3
per-area 3
strengthens
A 3-N nose-to-brain urolithin a nanomotor targeting microglial mitophagy in neuroinflammation.
03-apr-2026
novelty 3
per-area 3
strengthens